A novel dosage approach for evaluation of SMANCS [poly-(styrene-co-maleyl-half-n-butylate) - neocarzinostatin] in the treatment of primary hepatocellular carcinoma.

  • Authors:
    • L W Seymour
    • S P Olliff
    • C J Poole
    • P G De Takats
    • R Orme
    • D R Ferry
    • H Maeda
    • T Konno
    • D J Kerr
  • View Affiliations

  • Published online on: June 1, 1998     https://doi.org/10.3892/ijo.12.6.1217
  • Pages: 1217-1240
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

We report a Phase I/II clinical trial of poly-(styrene-co-maleyl-half-n-butylate)-neocarzinostatin (SMANCS) for intra-arterial treatment of hepatoma. Early patients received 4 or 8 mg SMANCS dissolved in Lipiodol; later patients were treated according to tumour size and degree of filling achieved. SMANCS/Lipiodol drained rapidly from normal liver but was retained within tumour interstitium. Tumour nodules filled with SMANCS/Lipiodol usually stabilised and often regressed. No UICC criteria-defined responses were achieved, partly due to difficulties of filling several lesions simultaneously. Signs of therapeutic activity suggest a more extensive clinical study is warranted.

Related Articles

Journal Cover

June 1998
Volume 12 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Seymour, L., Olliff, S., Poole, C., De Takats, P., Orme, R., Ferry, D. ... Kerr, D. (1998). A novel dosage approach for evaluation of SMANCS [poly-(styrene-co-maleyl-half-n-butylate) - neocarzinostatin] in the treatment of primary hepatocellular carcinoma.. International Journal of Oncology, 12, 1217-1240. https://doi.org/10.3892/ijo.12.6.1217
MLA
Seymour, L., Olliff, S., Poole, C., De Takats, P., Orme, R., Ferry, D., Maeda, H., Konno, T., Kerr, D."A novel dosage approach for evaluation of SMANCS [poly-(styrene-co-maleyl-half-n-butylate) - neocarzinostatin] in the treatment of primary hepatocellular carcinoma.". International Journal of Oncology 12.6 (1998): 1217-1240.
Chicago
Seymour, L., Olliff, S., Poole, C., De Takats, P., Orme, R., Ferry, D., Maeda, H., Konno, T., Kerr, D."A novel dosage approach for evaluation of SMANCS [poly-(styrene-co-maleyl-half-n-butylate) - neocarzinostatin] in the treatment of primary hepatocellular carcinoma.". International Journal of Oncology 12, no. 6 (1998): 1217-1240. https://doi.org/10.3892/ijo.12.6.1217